Related Experiment Videos
Secondary prevention and lipid lowering: results and implications
American Heart Journal
|November 1, 1985
Summary
Cholestyramine treatment significantly reduced cholesterol and LDL levels in patients with type II hyperlipidemia. This lipid-lowering intervention showed a positive effect on coronary artery disease (CAD) progression in this secondary prevention trial.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Coronary artery disease (CAD) is a significant health concern.
- Lipid management is crucial for secondary prevention in patients with hyperlipidemia.
Purpose of the Study:
- To evaluate the effect of lipid-lowering drug intervention on existing CAD progression.
- To assess cholestyramine's efficacy in type II hyperlipidemic patients over 5 years.
Main Methods:
- A randomized, secondary prevention trial involving 143 patients.
- Comparison of cholestyramine plus diet versus placebo plus diet.
- Assessment of CAD progression/regression using angiographic changes from baseline.
Main Results:
- Cholestyramine significantly reduced total cholesterol and LDL cholesterol compared to placebo.
- An 8% increase in HDL cholesterol was observed in the cholestyramine group.
- A statistically significant positive effect of cholestyramine was found in one category of CAD progression.
Conclusions:
- Cholestyramine treatment effectively lowers lipids in type II hyperlipidemic patients.
- The drug shows potential benefits in managing coronary artery disease progression as a secondary prevention strategy.